Native T1 and Extracellular Volume in Transthyretin Amyloidosis

Sipe, 2014, Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis, Amyloid, 21, 221, 10.3109/13506129.2014.964858 Rapezzi, 2009, Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types, Circulation, 120, 1203, 10.1161/CIRCULATIONAHA.108.843334 Pepys, 2006, Amyloidosis, Annu Rev Med, 57, 223, 10.1146/annurev.med.57.121304.131243 Fontana, 2014, Native T1 mapping in transthyretin amyloidosis, J Am Coll Cardiol Img, 7, 157, 10.1016/j.jcmg.2013.10.008 Fontana, 2015, Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis, Circulation, 132, 1570, 10.1161/CIRCULATIONAHA.115.016567 Perugini, 2005, Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy, J Am Coll Cardiol, 46, 1076, 10.1016/j.jacc.2005.05.073 Rapezzi, 2011, Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy, Eur J Nucl Med Mol Imaging, 38, 470, 10.1007/s00259-010-1642-7 Glaudemans, 2014, Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis, Amyloid, 21, 35, 10.3109/13506129.2013.871250 Maurer, 2015, Noninvasive Identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology, Am J Med, 128, 1275, 10.1016/j.amjmed.2015.05.039 Gillmore, 2018, A new staging system for cardiac transthyretin amyloidosis, Eur Heart J, 39, 2799, 10.1093/eurheartj/ehx589 Karamitsos, 2013, Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis, J Am Coll Cardiol Img, 6, 488, 10.1016/j.jcmg.2012.11.013 Banypersad, 2015, T1 mapping and survival in systemic light-chain amyloidosis, Eur Heart J, 36, 244, 10.1093/eurheartj/ehu444 Martinez-Naharro, 2017, Magnetic resonance in transthyretin cardiac amyloidosis, J Am Coll Cardiol, 70, 466, 10.1016/j.jacc.2017.05.053 Gillmore, 2016, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, Circulation, 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 Elliott, 2008, Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 29, 270, 10.1093/eurheartj/ehm342 Fontana, 2012, Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR, J Cardiovasc Magn Reson, 14, 88, 10.1186/1532-429X-14-88 White, 2013, T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique, J Am Coll Cardiol Img, 6, 955, 10.1016/j.jcmg.2013.01.011 Hutt, 2014, Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis, Eur Heart J Cardiovasc Imaging, 15, 1289, 10.1093/ehjci/jeu107 Fontana, 2015, Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study, Radiology, 277, 388, 10.1148/radiol.2015141744 Kotecha, 2017, Multiparametric mapping to understand pathophysiology in cardiac amyloidosis, Heart, 103, A1, 10.1136/heartjnl-2017-311399.1 Messroghli, 2017, J Cardiovasc Magn Reson, 19, 75, 10.1186/s12968-017-0389-8 McDonald, 2017, Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities, Radiology, 285, 546, 10.1148/radiol.2017161595